Published in Cancer Weekly, June 23rd, 2009
"Patients were eligible if they received <= 1 previous trastuzurnab regimen, <= 2 cytotoxic regimens for advanced breast cancer, and lifetime cumulative anthracycline doses <= 240 mg/m(2). The study regimen comprised...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.